| Literature DB >> 15755583 |
Yoko Kita1, Takao Tanaka, Shigeto Yoshida, Naoya Ohara, Yasufumi Kaneda, Sachiko Kuwayama, Yumiko Muraki, Noriko Kanamaru, Satomi Hashimoto, Hiroko Takai, Chika Okada, Yukari Fukunaga, Yayoi Sakaguchi, Izumi Furukawa, Kyoko Yamada, Yoshikazu Inoue, Yuji Takemoto, Mariko Naito, Takeshi Yamada, Makoto Matsumoto, David N McMurray, E C Dela Cruz, E V Tan, R M Abalos, J A Burgos, Robert Gelber, Yasir Skeiky, Steven Reed, Mitsunori Sakatani, Masaji Okada.
Abstract
We have developed two novel tuberculosis (TB) vaccines: a DNA vaccine combination expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) by using the hemagglutinating virus of Japan (HVJ)-liposome (HSP65+IL-12/HVJ) and a recombinant BCG harboring the 72f fusion gene (72f rBCG). These vaccines provide remarkable protective efficacy in mouse and guinea pig models, as compared to the current by available BCG vaccine. In the present study, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis, to evaluate the HSP65+IL-12/HVJ and 72f rBCG vaccines. Vaccination with HSP65+IL-12/HVJ as well as 72f rBCG vaccines provided better protective efficacy as assessed by the Erythrocyte Sedimentation Rate, chest X-ray findings and immune responses than BCG. Most importantly, HSP65+IL-12/HVJ resulted in an increased survival for over a year. This is the first report of successful DNA vaccination and recombinant BCG vaccination against M. tuberculosis in the monkey model.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15755583 DOI： 10.1016/j.vaccine.2005.01.057
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641